Renagade Therapeutics Management Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Renagade Therapeutics Management

Access the complete profile.

Renagade Therapeutics Management Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	4242 Drugs & Druggists' Sundries Merchant Wholesalers
Address	640 Memorial Drive 2nd Floor, Suite 2300 Cambridge, MA 02139

Note: Revenues for privately held companies are statistical evaluations.


Renagade Therapeutics Management's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Renagade Therapeutics Management's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Renagade Therapeutics Management is classified as operating in the Drugs & Druggists' Sundries Merchant Wholesalers industry, NAICS Code 4242.

Renagade Therapeutics Management Annual Revenue and Growth Rate

Renagade Therapeutics Management	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$100 - $500 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Renagade Therapeutics Management's revenues are gauged from an analysis of company filings.

Renagade Therapeutics Management's Income Statement (based on Industry Averages)

Renagade Therapeutics Management P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Renagade Therapeutics Management is developing and marketing. Renagade Therapeutics Management doesn't have any recent trademark applications, indicating Renagade Therapeutics Management is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
RNGD Pharmaceutical and biological preparations and substances, namely, preparations; Pharmaceutical preparations, namely, nucleic acid therapeutics and delivery vehicles being RNA and DNA therapeutics for scientific, research, medical, or pharmaceutical use; Pharmaceutical preparations, namely, nucleic acid therapeutics and delivery vehicles being RNA and DNA therapeutics which constitute and encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy, for scientific, research, medical, or pharmaceutical use; Human and veterinarian vaccine preparations; Vaccines; Anti-epileptic pharmaceutical preparations; Medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, reproductive disorders, infectious diseases for use in oncology; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations in the nature nucleic acid delivery agents; Chemical and biological reagents for medical or veterinary purposes, namely, for nucleic acid therapy; Biological preparations for medical, pharmaceutical or veterinary purposes, namely, for use in connection with nucleic acid therapy; Pharmaceutical and veterinary preparations, namely, nano particles to improve delivery of plasmid DNA and messenger RNA molecules; nano particles for the delivery of pharmaceutical or veterinary agents and preparations; nano particles for drug delivery; engineered nucleic acids for delivery of therapeutic DNA or mRNA sequences to cells, all for clinical use, medical use, clinical laboratory use, and medical laboratory use; Nucleic acid sequences and chemical reagents for medical and veterinary purposes; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Enzymes and nucleic acid sequences for medical use, namely, for the modification of cells and RNA and DNA; pharmaceutical preparations and therapeutic agents, namely, for gene therapy and RNA and DNA editing; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene, genome, and cellular editing, modulation, and modification for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; Enzymes, nucleic acid molecules, and compounds/agents for modifying small RNAs with targeting agents for medical use, namely, use of the modified small RNAs in the gene editing industry; pharmaceutical preparations and therapeutic agents, namely, for gene therapy and mRNA regulation; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation; Drug delivery agents in the form of pharmaceutical preparations, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds directed to lipid nanoparticles for the purpose of delivering pharmaceutical preparations to specific target tissue sites; drug delivery agents in the form of pharmaceutical preparations, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds and agents that facilitate the release and delivery of a wide variety of pharmaceutical preparations; drug delivery agents consisting of pharmaceutical preparations and therapeutic agents that facilitate the release and delivery of a wide variety of pharmaceutical preparations for RNA, gene therapy and mRNA regulation; drug delivery agents consisting of pharmaceutical and biological preparations for medical use that facilitate the release and delivery of a wide variety of pharmaceutical preparations for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; drug delivery agents consisting of pharmaceutical preparations that facilitate the release and delivery of a wide variety of pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation; pharmaceutical preparations, namely, vaccines; Pharmaceutical preparations, lipids, lipid nanoparticles, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds/agents for medical use	10/18/2023
CELEST Drug delivery agents in the form of pharmaceutical preparations, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds directed to lipid nanoparticles for the purpose of delivering pharmaceutical preparations to specific target tissue sites; drug delivery agents in the form of pharmaceutical preparations, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds and agents that facilitate the release and delivery of a wide variety of pharmaceutical preparations; drug delivery agents consisting of pharmaceutical preparations and therapeutic agents that facilitate the release and delivery of a wide variety of pharmaceutical preparations for RNA, gene therapy and mRNA regulation; drug delivery agents consisting of pharmaceutical and biological preparations for medical use that facilitate the release and delivery of a wide variety of pharmaceutical preparations for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; drug delivery agents consisting of pharmaceutical preparations that facilitate the release and delivery of a wide variety of pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation; pharmaceutical preparations, namely, vaccines	10/11/2023
PRL Pharmaceutical preparations, lipids, lipid nanoparticles, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds/agents for medical use; pharmaceutical preparations and therapeutic agents, namely, for RNA, gene therapy and mRNA regulation; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation	10/09/2023

See all trademarks and details in the Full Report.

Market Share of Renagade Therapeutics Management's Largest Competitors

A competitive analysis shows these companies are in the same general field as Renagade Therapeutics Management, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
AMERISOURCEBERGEN	Conshohocken, PA	100
MCKESSON	Irving, TX	58
CARDINAL HEALTH 119	Dublin, OH	42
TAKEDA PHARMACEUTICALS AMERICA	Lexington, MA	31
CATALENT PHARMA SOLUTIONS	Somerset, NJ	13
OWENS & MINOR DISTRIBUTION	Mechanicsville, VA	11
J M SMITH	Spartanburg, SC	3
DAIICHI SANKYO	Basking Ridge, NJ	3
HIKMA PHARMACEUTICALS USA	Berkeley Heights, NJ	2

Nearby Competitors

These companies are similar in business line and location to Renagade Therapeutics Management. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
RENAGADE THERAPEUTICS MANAGEMENT	Cambridge, MA	100
INMAN PHARMACY	Cambridge, MA	22
K36 THERAPEUTICS	Cambridge, MA	10
ATLANTIC CHEMICALS TRADING OF NORTH AMERICA	Boston, MA	6
DESIGN PHARMACEUTICALS	Cambridge, MA	3

Future Competition: Renagade Therapeutics Management's Fastest Growing Competitors

These companies are in the same general field as Renagade Therapeutics Management and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)